Wythe Therapeutics, Inc. (Wythe) and VeroScience LLC (Vero) just announced the completion of the worldwide exclusive license for the manufacture, marketing and distribution of Cycloset® from Vero to Wythe.
Cycloset® is a patented novel oral formulation of bromocriptine mesylate, for the treatment of Type-2 Diabetes that Vero is seeking approval to market. According to Charles P. Sutphin, CEO of Wythe:
If approved, Cycloset® will be a 'First in Class' compound in the treatment of Type II Diabetes utilizing a CNS mode of action.
Type 2 Diabetes currently affects over 20 million Americans, and the number of affected individuals is growing over 5% annually. Wythe believes Cycloset® will provide patients and doctors a new and additive weapon in the treatment of this devastating disease, which is nearing pandemic proportions.
While Vero is managing the the completion of the Cycloset(R) phase III b safety trial in the coming months, Wythe's responsibility will be focused on preparing for the commercialization of Cycloset® in the United States and Canada.
Read more of the press release.
Comment Preview